SCHEMBL23042885

SCHEMBL23042885

CC(=O)NCc1ncc(C)nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.41
MAPKAPK2 P49137 9/20 0.37
ALOX15 P16050 1/20 0.37
SETDB1 Q15047 1/20 0.36
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
VHL P40337 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NOTUM Q6P988 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 2/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13945229 0.87 NPSR1 (0.41) NPSR1MAPKAPK2ALOX15SETDB1KDM4E
SCHEMBL17423463 0.85 MAPKAPK2 (0.46) NPSR1MAPKAPK2L3MBTL1
SCHEMBL31373452 0.85 MAPKAPK2 (0.46) NPSR1MAPKAPK2L3MBTL1
SCHEMBL23042834 0.79 ALDH1A1 (0.36) MAPKAPK2KDM4EALDH1A1POLBSMN1; SMN2
SCHEMBL23042836 0.76 NPSR1 (0.42) NPSR1MAPKAPK2ALOX15SETDB1KDM4E
SCHEMBL13201540 0.76 NPSR1 (0.42) NPSR1MAPKAPK2ALOX15SETDB1VHL
SCHEMBL11328853 0.73 ALDH1A1 (0.39) KDM4ENOTUMALDH1A1POLBMAPK1
SCHEMBL14022776 0.73 MAPKAPK2 (0.38) MAPKAPK2ALDH1A1MAPK1SMN1; SMN2
SCHEMBL3842334 0.71 S1PR4 (0.36) ALDH1A1POLBMAPK1SMN1; SMN2
SCHEMBL11330035 0.71 KMT2A (0.31) NPSR1ALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331054-B2 Perk inhibiting imidazolopyrazine compounds HIBERCELL, INC. (US) 2025-06-17 US disclosed
US-20220348583-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS HIBERCELL, INC. 2022-11-03 US disclosed
US-20220348584-A1 PERK INHIBITING INDOLINYL COMPOUNDS HIBERCELL, INC. 2022-11-03 US disclosed
US-20220348584-A1 PERK INHIBITING INDOLINYL COMPOUNDS HIBERCELL, INC. 2022-11-03 US disclosed
WO-2021231784-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS HIBERCELL, INC. (US) 2021-11-18 WO disclosed
WO-2021041970-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 WO disclosed
WO-2021041970-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 WO disclosed
WO-2021041976-A1 PERK INHIBITING INDOLINYL COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 WO disclosed
WO-2021041976-A1 PERK INHIBITING INDOLINYL COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348583-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS MAPKAPK2, MAPK4, MAP3K5 NPSR1 4552/4885MAPKAPK2 1/4885ALOX15 2974/4885
US-12331054-B2 Perk inhibiting imidazolopyrazine compounds MAPKAPK2, MAPK4, MAP3K5 NPSR1 4552/4885MAPKAPK2 1/4885ALOX15 2974/4885
US-20220348584-A1 PERK INHIBITING INDOLINYL COMPOUNDS ATF4, MAP3K10, EEF2K NPSR1 4109/4885MAPKAPK2 8/4885ALOX15 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.